Subscribe Sign In Register

Premium

How ValueAct Shook Off Its Big Loss from Valeant

The hedge fund firm, headed by Jeff Ubben, did not suffer the same fate as other major shareholders of the ailing pharmaceutical concern.

By Stephen Taub Stephen Taub
January 6, 2017
Valeant Pharmaceuticals Offices Ahead Of Earnings Figures

Valeant Pharmaceuticals International Inc. headquarters stands in Bridgewater Township, New Jersey, U.S., on Thursday, Aug. 4, 2016. Valeant Pharmaceuticals International Inc. is scheduled to release earnings figures on Aug. 9. Photographer: Ron Antonelli/Bloomberg

Ron Antonelli/Bloomberg

Valeant Pharmaceuticals Offices Ahead Of Earnings Figures

Valeant Pharmaceuticals International Inc. headquarters stands in Bridgewater Township, New Jersey, U.S., on Thursday, Aug. 4, 2016.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Pharmaceutical Valueact Jeff Ubben Valiant
Related
Art_RAcapital_0423.jpg
Hedge Funds
RA Capital’s Buying Spree
Stephen Taub
April 23, 2024
discoverycapital_0422.jpg
Hedge Funds
Discovery Is Off to a Strong Start
Stephen Taub
April 22, 2024
Gold in Turbulent Times
Sponsored
The Role of Gold in Turbulent Times